Roivant Sciences Ltd.
ROIV
$11.92
$0.110.93%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -71.33% | -16.06% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -71.33% | -16.06% | |||
| Cost of Revenue | 5.19% | 3.49% | |||
| Gross Profit | -9.41% | -4.83% | |||
| SG&A Expenses | -43.69% | 72.04% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -24.67% | 36.78% | |||
| Operating Income | 23.70% | -38.59% | |||
| Income Before Tax | -32.61% | 13.41% | |||
| Income Tax Expenses | -90.57% | 292.90% | |||
| Earnings from Continuing Operations | -8.53% | -20.79% | |||
| Earnings from Discontinued Operations | -- | -100.00% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 10.14% | -10.54% | |||
| Net Income | -8.18% | -221.90% | |||
| EBIT | 23.70% | -38.59% | |||
| EBITDA | 22.26% | -36.50% | |||
| EPS Basic | -12.47% | -224.53% | |||
| Normalized Basic EPS | 24.96% | -91.83% | |||
| EPS Diluted | -12.40% | -226.28% | |||
| Normalized Diluted EPS | 24.96% | -91.83% | |||
| Average Basic Shares Outstanding | -3.82% | -2.13% | |||
| Average Diluted Shares Outstanding | -3.82% | -2.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||